A manually actuated chromatography device comprising a chamber for receiving a liquid sample, a pump with a metering valve, and a chromatography element, wherein the pump moves a predetermined volume of liquid from the sample chamber to the chromatography element.
F04B 9/12 - "Machines" ou pompes à piston caractérisées par les moyens entraînants ou entraînés liés à leurs organes de travail les moyens étant à fluide le fluide étant compressible, p. ex. de la vapeur ou de l'air
G01N 30/14 - Préparation par élimination de certains composants
B01D 15/12 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives à la préparation de l'alimentation
B01D 15/34 - Séparation par sélection en fonction de la taille, p. ex. chromatographie d'exclusion de tailleFiltration sur gelPerméation
G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p. ex. la chromatographie
2.
6-acetylmorphine analogs, and methods for their synthesis and use
The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
A61K 39/385 - Haptènes ou antigènes, liés à des supports
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
C07D 489/00 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 16/06 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux provenant de sérum
C07K 16/44 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs
G01N 33/94 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des narcotiques
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
(1) Control preparations for in vitro diagnostic testing, screening, confirmation and analysis; diagnostic reagents and chemical reagents, for laboratory or research use; solutions used in diagnostic test kits, for laboratory or research use; diagnostic test kits for laboratory use; diagnostic preparations for laboratory use; diagnostic test kits comprising reagents and assays.
(2) Medical diagnostic test kits; medical diagnostic reagents; diagnostic preparations for medical purposes; testing preparations for medical use; diagnostic tests for medical use; medical diagnostic assays; solutions used in medical diagnostic test kits; cartridges containing reagents for medical diagnostic test use; cartridges containing medical diagnostic reagents; test cartridges containing chemical reagents for in vitro diagnostic medical testing; medical reagents contained in a cartridge for medical diagnostic use.
(3) In vitro medical diagnostic instruments; in vitro medical diagnostic instruments for lipid testing; medical diagnostic blood testing instruments; medical diagnostic glucose testing instruments; medical diagnostic instruments for testing cholesterol; medical diagnostic instruments for therapeutic monitoring of heart disease and diabetes; test cassettes for use in relation to all the aforementioned goods.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Control preparations for in vitro diagnostic testing, screening, confirmation and analysis; diagnostic reagents and chemical reagents, for laboratory or research use; solutions used in diagnostic test kits, for laboratory or research use; diagnostic test kits for laboratory use; diagnostic preparations for laboratory use; diagnostic test kits comprising reagents and assays. Medical diagnostic test kits; medical diagnostic reagents; diagnostic preparations for medical purposes; testing preparations for medical use; diagnostic tests for medical use; medical diagnostic assays; solutions used in medical diagnostic test kits; cartridges containing reagents for medical diagnostic test use; cartridges containing medical diagnostic reagents; test cartridges containing chemical reagents for in vitro diagnostic medical testing; medical reagents contained in a cartridge for medical diagnostic use. In vitro medical diagnostic instruments; in vitro medical diagnostic instruments for lipid testing; medical diagnostic blood testing instruments; medical diagnostic glucose testing instruments; medical diagnostic instruments for testing cholesterol; medical diagnostic instruments for therapeutic monitoring of heart disease and diabetes; test cassettes for use in relation to all the aforementioned goods.
5.
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use
The present invention relates to novel 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
C07D 207/20 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
A61K 39/385 - Haptènes ou antigènes, liés à des supports
C07K 16/44 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs
G01N 33/94 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des narcotiques
C07D 207/267 - Pyrrolidones-2 avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux autres atomes de carbone du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement à l'atome d'azote du cycle
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
6.
DETECTION OF RECOMBINASE POLYMERASE AMPLIFICATION USING DUAL-HAPTEN PROBE
This disclosure relates to methods and compositions for detecting a target nucleic acid sequence using a dual-hapten probe. More specifically, the present disclosure relates to using recombinase polymerase amplification (RPA) and a dual-hapten probe to detect a target nucleic acid sequence. In some cases, the detection is on lateral flow strips.
C12Q 1/683 - Tests d’hybridation pour la détection de mutation ou de polymorphisme faisant intervenir des enzymes de restriction, p. ex. polymorphisme de longueur de fragment de resctriction
A manually actuated chromatography device comprising a chamber for receiving a liquid sample, a pump with a metering valve, and a chromatography element, wherein the pump moves a predetermined volume of liquid from the sample chamber to the chromatography element.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 30/14 - Préparation par élimination de certains composants
G01N 30/20 - Injection utilisant une valve d'échantillonnage
F04B 9/12 - "Machines" ou pompes à piston caractérisées par les moyens entraînants ou entraînés liés à leurs organes de travail les moyens étant à fluide le fluide étant compressible, p. ex. de la vapeur ou de l'air
F04B 13/00 - Pompes spécialement modifiées pour débiter des quantités fixes ou prédéterminées
B01D 15/12 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives à la préparation de l'alimentation
G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p. ex. la chromatographie
A microfluidic device includes an inlet port configured to receive a sample, a first reaction chamber fluidically coupled to the inlet port, a first pump fluidically coupled to the inlet port, a second pump fluidically coupled to a mixing chamber, a metering channel fluidically coupled to the first reaction chamber and to the mixing chamber, and one or more second reaction chambers fluidically coupled to the mixing chamber. The first pump is configured to move fluid from the inlet port to the first reaction chamber and from the first pump to the inlet port. The second pump is configured to move fluid from the second pump to the mixing chamber, from the first reaction chamber to the mixing chamber, and from the mixing chamber to the one or more second reaction chambers.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
9.
2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE
The present invention relates to novel 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
C07D 207/02 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle
C07D 207/18 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique
The present invention relates to novel 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine analogs: and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
C07D 207/02 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle
C07D 207/18 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique
The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
A61K 39/385 - Haptènes ou antigènes, liés à des supports
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
C07D 489/00 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule
C07K 16/44 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs
C07K 16/06 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux provenant de sérum
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
G01N 33/94 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des narcotiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A flu assay system including a sample module, a microfluidic nucleic acid amplification device, and an analyzer to facilitate fully automated nested recombinase polymerase amplification (RPA) on a sample delivered to the nucleic acid amplification device via the sample module. The assay includes providing a sample to a microfluidic device, and amplifying a target polynucleotide sequence in the sample. Amplifying the target polynucleotide sequence includes performing a first round of amplification on the sample to yield a first amplification product, and performing a second round of amplification on the first amplification product to yield a second amplification product. The second amplification product includes a smaller sequence completely contained within the first amplification product produced during the first round of amplification.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
13.
REDOX LABELED OLIGONUCLEOTIDE PROBES AND THEIR USE
This invention relates to sequence specific electrochemically-labeled oligonucleotide probes for the detection of nucleic acids and methods associated therewith.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A manually actuated chromatography device comprising a chamber for receiving a liquid sample, a pump with a metering valve, and a chromatography element, wherein the pump moves a predetermined volume of liquid from the sample chamber to the chromatography element.
The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
A61K 39/385 - Haptènes ou antigènes, liés à des supports
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
C07D 489/00 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 16/06 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux provenant de sérum
C07K 16/44 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs
G01N 33/94 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des narcotiques
The present invention provides for a home test assay or device that can calculate insulin on board levels, and uses thereof for improving insulin bolus calculation and prevention of hypoglycemia in e.g. Type-1 diabetes patients.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
18.
6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE
The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
C07D 489/00 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
C07D 489/02 - Composés hétérocycliques contenant des systèmes cycliques 4 aH-8, 9 c-imino-éthano-phénantro [4, 5-b, c, d] furanne, p. ex. dérivés d'époxy-4, 5 morphinane de formule avec des atomes d'oxygène liés en position 3 et 6, p. ex. morphine, morphinone
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug testing kits comprised of medical diagnostic reagents and assays that test for the presence of drugs and alcohol.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug testing kits comprised of medical diagnostic reagents and assays that test for the presence of drugs and alcohol.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug testing kits comprised of medical diagnostic reagents and assays that test for the presence of drugs and alcohol.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug testing kits comprised of medical diagnostic reagents and assays that test for the presence of drugs and alcohol.
The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby.
G01N 31/00 - Recherche ou analyse des matériaux non biologiques par l'emploi des procédés chimiques spécifiés dans les sous-groupesAppareils spécialement adaptés à de tels procédés
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug testing kits comprised of medical diagnostic reagents and assays that test for the presence of drugs and alcohol
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug testing kits comprised of medical diagnostic reagents and assays that test for the presence of drugs and alcohol
33.
METHODS FOR DIAGNOSING AND PROGNOSING PLACENTAL DYSFUNCTION AND PRE-ECLAMPSIA
Provided herein are methods for determining placental dysfunction in a female suspected of having placental dysfunction or preclampsia by assessing the expression of P1GF in a biological sample of a female patient who is less than 35 weeks pregnant. Also described herein are methods for assigning a prognosis for a future complication associated with pregnancy in a female suspected of having placental dysfunction who is less than 35 weeks pregnant. The invention further relates to methods of managing and mitigating risks of pregnant females suspected of having placental dysfunction or pre-eclampsia to monitor the health and well-being of the baby and mother. Said methods can be used at the time of initial assessment for suspected placental dysfunction or pre-clampsia to identify a group of pregnant females with a placental dysfunction or pre-eclampsia, and to determine the potential to develop any complications of placental dysfunction or pre-eclampsia. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate pregnant female likely to benefit from early and aggressive pre-eclampsia therapy.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
The present invention relates to methods for joining materials as well as articles manufactured using such processes. The invention pertains to a process for joining a first substrate to a second substrate. The process includes irradiating a portion of a first substrate with a laser beam having a first wavelength and intensity sufficient to increase the absorbance of the first substrate to light having a second, different wavelength. The laser beam may carbonize at least a portion of the irradiated portion of the first substrate imparting a higher absorbance to light than non-irradiated portions of the first substrate. A second substrate is then placed in contact with the irradiated portion of the first substrate. The first substrate is then irradiated with a second laser having a second wavelength, different to the first wavelength; with a sufficient intensity to heat and, preferably melt, the irradiated portion of the first substrate.
A combination of capillary forces and gas pressure is used to control the movement of liquid samples within a microfluidic device. A liquid sample introduced to a proximal portion of a capillary channel of a microfluidic device moves by capillary action partway along the capillary channel. As the liquid sample moves, a pressure of a gas acting upon a distal gas-liquid interface of the liquid sample increases by an amount sufficient to stop further movement of the liquid sample. To initiate further movement of the liquid sample, a pump connected to a distal portion of the capillary channel decreases the pressure of the gas acting upon the distal gas-liquid interface of the liquid sample by an amount sufficient to permit the liquid sample to move by capillary action further along the capillary channel of the microfluidic device.
A microfluidic pump is provided for managing fluid flow in disposable assay devices, which provides constant flows even at very low flow rates. Devices utilizing the microfluidic pump, as well as methods for manufacture and performing a microfluidic process are also provided.
The invention encompasses diagnosis and prognosis in the context of heart or renal failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The invention also relates to methods of assigning an increased likelihood that a subject having CKD is susceptible to CKD progression. The invention relates in part to assigning a diagnosis of heart and/or renal failure, and/or an outcome risk (e.g., worsening cardiac and/or renal function or a mortality risk) to a subject based, at least in part, on the result(s) obtained from an assay that detects WAP four-disulfide core domain protein 2 performed on a body fluid sample obtained from a subject..
The present invention relates to novel 2-hydroxyhippuric acid analogs, and methods for their synthesis and use. Such analogs are designed to provide a protected or functional moiety such as a free thiol (-SH) group or a protected thiol group, thereby providing a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Diagnostic preparations for medical purposes, specifically in vitro diagnostic immunoassay systems and components thereof for determining the presence of drugs of abuse in fluid and/or tissues samples of human subjects.
41.
METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS IN GASTRIC CANCER
The present invention relates to methods for diagnosing gastric cancer; methods for assigning risk of reoccurrence of gastric cancer; methods for assigning risk of mortality due to gastric cancer, methods of monitoring gastric cancer; methods of staging gastric cancer; and various devices and kits adapted to perform such methods. These methods comprise measurement of Trefoil factor (1) and optionally Anterior gradient protein (2) homolog on a body fluid sample obtained from a subject.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
42.
METHODS AND COMPOSITIONS FOR MONITORING HEART FAILURE
The present invention provides methods and compositions for monitoring of subjects suffering from, or being evaluated for, heart failure. A filtered Natriuretic peptide time-series, alone or in combination with other clinical indicia such as weight gain, can be used to estimate a patient's hazard (risk of decompensation). The cumulative integral of Natriuretic peptide concentration can be used to estimate cumulative hazard (risk times exposure) over longer periods of exposure, e.g., 14 day periods, or 30 day periods.
The invention encompasses diagnosis and prognosis in the context of heart or renal failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The invention also relates to methods of assigning an increased likelihood that a subject having AKI is susceptible to AKI progression. The invention relates in part to assigning a diagnosis of heart and/or renal failure, and/or an outcome risk (e.g., worsening cardiac and/or renal function or a mortality risk) to a subject based, at least in part, on the result(s) obtained from an assay that detects WAP four-bisulfide core domain protein 2 performed on a body fluid sample obtained from a subject.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A process includes providing a mixture that includes a recombinase, a single-strand binding protein, and one or more oligonucleotides; and detecting particles in the reaction mixture.
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby.
A method includes contacting a crude matrix with components of an isothermal nucleic acid amplification reaction for a target nucleic acid species, thereby providing a mixture; incubating the mixture under conditions sufficient for the isothermal nucleic acid amplification reaction to proceed, thereby providing a product; and determining whether an indicator of the target nucleic acid species is present in the product.
This disclosure describes kits, reagents and methods for Recombinase Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed kits, reagents and methods have the advantage of not requiring thermocycling or thermophilic enzymes, thus offering easy and affordable implementation and portability relative to other amplification methods.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
50.
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
The present invention relates to methods and compositions for diagnosing SIRS, sepsis, severe sepsis, septic shock, or MODS in a subject, or assigning a prognostic risk for one or more clinical outcomes for a subject suffering from SIRS, sepsis, severe sepsis, septic shock, or MODS, the method comprising performing an immunoassay for CCL23 splice variant.
The present invention relates to methods for the diagnosis and evaluation of BNP- related diseases. In particular, patient test samples are analyzed for the presence and amount of a plurality of natriuretic peptides, and a combined natriuretic peptide result is used as a diagnostic marker.
An assay device and method for measuring the concentration of LDL-associated cholesterol in a blood-fluid sample are described. The method employs selective precipitation of VLDL and chylomicrons and immunoseparation of HDL from a blood fluid sample. The assay device allows the assay to be performed entirely in a flow strip format.
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Reagents for use in scientific and/or medical research uses, namely antibodies, fluorescent compounds for use as detectable labels, immunoassay standards, and buffer solutions Biological reagents, namely antibodies for medical and veterinary diagnostic and therapeutic use in a wide variety of illnesses and diseases Laboratory analyte testing apparatuses, namely fluorometers, immunoassay devices, pipets, and electronic storage media containing encoded testing parameters, for detection of drugs of abuse, microbes, and markers related to a wide variety of illnesses and diseases Medical diagnostic testing apparatuses, namely fluorometers, immunoassay devices, and electronic storage media containing encoded testing parameters, for detection of drugs of abuse, microbes, and markers related to a wide variety of illnesses and diseases Scientific and medical research services, namely generation of antibodies and antibody expression libraries, diagnostic assay design and development, and identification and validation of diagnostic and therapeutic targets
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
laboratory devices for scientific research use in analyzing the composition of the biological samples for determining the presence or amount of markers related to the cardiovascular diseases in humans [ and non-human animals ] medical devices for analyzing the composition of human [ and veterinary ] clinical samples, namely, determining the presence or amount of markers related to heart disease
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Diagnostic test kits comprising reagents and reagent vesicles for performing diagnostic test assay.
(2) Diagnostic test devices and kits comprising pipette for performing diagnostic test assay.
(3) Diagnostic test devices and kits comprising support device for performing diagnostic test assay. (1) Diagnostic marker discovery, namely analytical laboratory testing services for the purpose of identifying diagnostic genetic markers; laboratory testing services, namely, immunoassay-based drug testing services.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical, veterinary and sanitary substances; infants' and invalids' foods; plasters, material for bandaging; material for stopping teeth, dental wax; disinfectants; preparations for killing weeds and destroying vermin; diagnostic reagents for in vivo use. Surgical, medical, dental and veterinary instruments and apparatus , artificial limbs, eyes and teeth; orthopedic articles; suture materials; blood testing apparatus; blood drawing apparatus; blood coagulation monitoring, measuring or analysis apparatus; hemostatis monitoring, measuring or analysis apparatus. Medical, hygienic and beauty care; pharmaceutical, scientific, medical and industrial research; laboratory services; veterinary and agricultural services; consultancy, design, testing, and advisory services in the fields of medicine, surgery, diagnosis, pharmaceuticals, hospitals and patient care; information and advisory services relating to the aforesaid, including the provision of information relating to the aforesaid on-line from a computer network or via the interner.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
Produits et services
Chemicals for use in science and scientific research; reagents and other chemicals which detect immune complexes in body fluids for scientific or research use; immunodiagnostic assay test kits containing such chemicals. Pharmaceutical and veterinary preparations; chemical and diagnostic reagents for medical or veterinary use. Scientific apparatus and instruments; laboratory apparatus and instruments; test tubes, pipettes and immunoassay diagnostic slides.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Laboratory diagnostic test kits containing antibodies, reagents, reagent vesicles, support racks, and pipettes; laboratory analyte testing apparatus, namely test kits for detection of abused drugs and metabolites thereof. (1) Research and consultation services in biotechnology and laboratory services, namely assay design, purification, processing and development of diagnostics and the products of biotechnology.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
Produits et services
medical laboratory diagnostic test kits containing antibodies, reagents, reagent vesicles, support racks, and pipettes laboratory analytical testing apparatus for detection of abused drugs
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
16 - Papier, carton et produits en ces matières
Produits et services
(1) In vitro medical diagnostic equipment, namely, printers.
(2) In vitro medical diagnostic equipment, namely, photometers, disposable test cassettes, collection tubes and pipettes, and kits containing the above goods, carrying cases.
(3) In vitro medical diagnostic equipment, namely, instruction manuals.
physician (and allied health care professionals) office system for monitoring blood lipids, comprising a photometer, disposable test cassettes and blood collection accessories